Cargando…
Innovative Vaccines to Fight COVID-19, Other Viruses
COVID-19 added urgency to the quest for the development of new vaccines, and academic researchers and biotechnology companies responded by capitalizing on already-in-the-pipeline advances and swiftly transitioning products from the lab to the clinic. Their efforts reaped rewards. According to a U.S....
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
IEEE
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905606/ https://www.ncbi.nlm.nih.gov/pubmed/34982663 http://dx.doi.org/10.1109/MPULS.2021.3128986 |
| _version_ | 1784665223931625472 |
|---|---|
| collection | PubMed |
| description | COVID-19 added urgency to the quest for the development of new vaccines, and academic researchers and biotechnology companies responded by capitalizing on already-in-the-pipeline advances and swiftly transitioning products from the lab to the clinic. Their efforts reaped rewards. According to a U.S. Department of Health and Human Services analysis, the COVID vaccines delivered in the USA from January to May 2021 resulted in 39,000 fewer deaths and 107,000 fewer hospitalizations, and prevented another 265,000 cases among Medicare recipients alone [1]. |
| format | Online Article Text |
| id | pubmed-8905606 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | IEEE |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89056062022-05-13 Innovative Vaccines to Fight COVID-19, Other Viruses IEEE Pulse Article COVID-19 added urgency to the quest for the development of new vaccines, and academic researchers and biotechnology companies responded by capitalizing on already-in-the-pipeline advances and swiftly transitioning products from the lab to the clinic. Their efforts reaped rewards. According to a U.S. Department of Health and Human Services analysis, the COVID vaccines delivered in the USA from January to May 2021 resulted in 39,000 fewer deaths and 107,000 fewer hospitalizations, and prevented another 265,000 cases among Medicare recipients alone [1]. IEEE 2021-12-31 /pmc/articles/PMC8905606/ /pubmed/34982663 http://dx.doi.org/10.1109/MPULS.2021.3128986 Text en This article is free to access and download, along with rights for full text and data mining, re-use and analysis. |
| spellingShingle | Article Innovative Vaccines to Fight COVID-19, Other Viruses |
| title | Innovative Vaccines to Fight COVID-19, Other Viruses |
| title_full | Innovative Vaccines to Fight COVID-19, Other Viruses |
| title_fullStr | Innovative Vaccines to Fight COVID-19, Other Viruses |
| title_full_unstemmed | Innovative Vaccines to Fight COVID-19, Other Viruses |
| title_short | Innovative Vaccines to Fight COVID-19, Other Viruses |
| title_sort | innovative vaccines to fight covid-19, other viruses |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905606/ https://www.ncbi.nlm.nih.gov/pubmed/34982663 http://dx.doi.org/10.1109/MPULS.2021.3128986 |
| work_keys_str_mv | AT innovativevaccinestofightcovid19otherviruses |